临床肿瘤学杂志

参考文献

[1]范奎，代良敏，伍振峰，等．放化疗所致骨髓抑制的研究进展[J]．中华中医药杂志，2017,32(1):210-214.

[2]马军，王杰军，张力，等．肿瘤相关性贫血临床实践指南(2015—2016版)[J]．中国实用内科杂志，2016,36(S1):1-21.

[3] Becker PS,Griffiths EA,Alwan LM,et al. NCCN guidelines insights:Hematopoietic growth factors,version 1. 2020[J]. J Nat Compr Cancer Netw,2020,18(1):12-22.

[4] Wu Y,Aravind S,Ranganathan G,et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors:a descriptive study of a large outpatient oncology practice database,2000-2007[J/OL]. Clin Ther,2009[2021-06-10]. https://pubmed.ncbi.nlm.nih.gov/20110050/．

[5] Lyman GH,Abella E,Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy:A systematic review[J]. Crit Rev Oncol hematol,2014,90(3):190-199.

[6] Klastersky J,Paesmans M,Rubenstein EB,et al. The Multinational Association for Supportive Care in Cancer risk index:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients[J]. J Clin Oncol,2000,18(16):3038-3051.

[7]刘小军，周圆．造血微环境与骨髓增殖性肿瘤[J]．中国实用内科杂志，2019,39(2):149-152.

[8]王珏，陈朝辉，邵科钉，等．龟鹿二仙胶逆转化疗诱导的造血干细胞衰老的机制研究[J]．浙江中医药大学学报，2018,42(6):419-425.

[9]张先平，王乾兴，陈斌，等．当归多糖对小鼠衰老造血干细胞细胞周期蛋白的调控[J]．基础医学与临床，2013,33(3):320-324.

[10]熊丽溶，宋小英，景鹏伟，等．5-氟尿嘧啶损伤骨髓基质细胞致造血细胞应激诱导性早衰[J]．中国实验血液学杂志，2017,25(4):1178-1186.

[11] Hopkins TA,Ainsworth WB,Ellis PA,et al. PARP1 Trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow[J]. Mol Cancer Res,2019,17(2):409-419.

[12] Farrés J,Llacuna L,Martin-Caballero J,et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors[J]. Cell Death Diff,2015,22(7):1144-1157.

[13]李进，秦叔逵，马军，等主编．中国临床肿瘤学会(CSCO)常见恶性肿瘤诊疗指南[M]．北京:人民卫生出版社，2019:486-487.

[14] National Institutes of Health,National Cancer Institute. Common terminology criteria for adverse events(CTCAE)(version 5. 0)[EB/OL].2017[2021-06-15].https://ctep.cancer.gov/protocol Development/electronic_applications/docs/CTCAE_v5_Quick_Reference_8. 5x11. pdf.

[15] World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity[EB/OL]. 2011[2021-06-15]. https://www. who. int/vmnis/indicators/haemoglobin.pdf.

[16]中国临床肿瘤学会指南工作委员会．肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J]．中华肿瘤杂志，2017,39(11):868-878.

[17]史艳侠，邢镨元，张俊，等．中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J]．中国肿瘤临床，2019,46(17):869-875.

[18]中国临床肿瘤学会肿瘤化疗所致血小板减少症共识专家委员会．肿瘤化疗所致血小板减少症诊疗中国专家共识(2018版)[J]．中华肿瘤杂志，2018,40(9):714-720.

[19]田劭丹，董青，祁烁，等．化疗后白细胞减少症中医药防治与评估专家共识[J]．现代中医临床，2018,25(3):1-6.

[20]侯丽，董青，田劭丹，等．肿瘤相关性贫血中医药防治专家共识[J]．北京中医药，2021,40(1):48-52.

[21]史艳侠，邢镨元，张俊，等．肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版)[J]．中国肿瘤临床，2019,46(17):876-882.

[22]史艳侠，邢镨元，张俊，等．中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]．中国肿瘤临床，2019,46(18):923-929.

[23]陈露，孔天东，段方方，等．重组人血小板生成素对化疗相关性血小板减少症的预防作用[J]．肿瘤基础与临床，2020,33(3):222-225.

[24] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology,cancer-and chemotherapy-induced anemia version 1. 2018[EB/OL]. 2018[2021-06-30]. https://oncolife.com. ua/doc/nccn/Cancer-and_Chemotherapy-Induced_Anemia.pdf.

[25] Tralongo AC,Antonuzzo A,Pronzato P,et al. Management of chemotherapy-induced neutropenia in patients with cancer:2019guidelines of the Italian Medical Oncology Association(AIOM)[J]. Tumori,2020,106(4):273-280.

[26] Aguado JM, Cruz JJ, Virizuela JA, et al. Management of infection and febrile neutropenia in patients with solid cancer[J].Enferm Infecc Microbiol Clin,2017,35(7):451-460.

[27] de Naurois J,Novitzky-Basso I,Gill MJ,et al. Management of febrile neutropenia:ESMO clinical practice guidelines[J]. Ann Oncol,2010,21(Suppl 5):v252-v256.

[28] Aapro M,Boccia R,Leonard R,et al. Refining the role of pegfilgrastim(a long-acting G-CSF)for prevention of chemotherapy-induced febrile neutropenia:consensus guidance recommendations[J]. Support Care Cancer,2017,25(11):3295-3304.

[29]中国临床肿瘤学会抗淋巴瘤联盟，中国临床肿瘤学会抗白血病联盟，中国临床肿瘤学会抗肿瘤药物安全管理专家委员会，等．重组人白介素-11防治血小板减少症临床应用中国专家共识(2021年版)[J]．临床肿瘤学杂志，2020,25(12):1129-1137.

[30]张荣侠．重组人促血小板生成素与白介素-11治疗恶性肿瘤化疗后血小板减少症的疗效评价[J]．临床医药文献电子杂志，2019,6(84):180-181.

[31]抗白血病联盟中国临床肿瘤学会CSCO，抗淋巴瘤联盟中国临床肿瘤学会CSCO．急性白血病化疗所致血小板减少症诊疗中国专家共识[J]．白血病·淋巴瘤，2019(4):193-197.

[32]李焕，刘洪悦，张志圣，等．化疗所致血小板减少症的治疗药物选择[J]．中国药学杂志，2018,53(6):467-471.

[33]马军，朱军，徐兵河，等．聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)临床应用中国专家共识[J]．中国肿瘤临床，2016,43(7):271-274.

[34]马军，王杰军，张力，等．肿瘤相关性贫血临床实践指南(2015—2016版)[J]．中国实用内科杂志，2015,35(11):921-930.

[35] Bohlius J,Bohlke K,Castelli R,et al. Management of cancerassociated anemia with erythropoiesis-stimulating agents:ASCO/ASH clinical practice guideline update[J]. J Clin Oncol,2019,37(15):1336-1351.

[36] Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer[J]. Cochrane Database System Rev,2012,12(12):D3407.

[37] Pirker R,Hedenus M,Vansteenkiste J,et al. Effectiveness of darbepoetin alfa for chemotherapy-induced anemia when initiated at hemoglobin≤10 g/dL[J]. Clin Ther,2016,38(1):122-135.

[38] Wiesen AR,Hospenthal DR,Byrd JC,et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding.[J]. Ann Int Med,1994,121(4):230-278.